| __timestamp | Gilead Sciences, Inc. | Veracyte, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 3788000000 | 16606000 |
| Thursday, January 1, 2015 | 4006000000 | 21497000 |
| Friday, January 1, 2016 | 4261000000 | 25462000 |
| Sunday, January 1, 2017 | 4371000000 | 28195000 |
| Monday, January 1, 2018 | 4853000000 | 33078000 |
| Tuesday, January 1, 2019 | 4675000000 | 36523000 |
| Wednesday, January 1, 2020 | 4572000000 | 41455000 |
| Friday, January 1, 2021 | 6601000000 | 74400000 |
| Saturday, January 1, 2022 | 5657000000 | 101582000 |
| Sunday, January 1, 2023 | 6498000000 | 112903000 |
| Monday, January 1, 2024 | 28675800000 |
Infusing magic into the data realm
In the ever-evolving landscape of biotechnology, Gilead Sciences, Inc. and Veracyte, Inc. have carved distinct paths. From 2014 to 2023, Gilead's cost of revenue surged by approximately 72%, peaking in 2021 with a notable 43% increase from the previous year. This reflects Gilead's aggressive expansion and investment in groundbreaking therapies. Meanwhile, Veracyte, a rising star in genomic diagnostics, saw its cost of revenue grow by an impressive 580% over the same period, highlighting its rapid scaling and market penetration.
While Gilead's cost of revenue consistently dwarfs Veracyte's, the latter's growth trajectory underscores its potential in the precision medicine arena. As the biotech sector continues to innovate, these trends offer a glimpse into the strategic priorities and market dynamics shaping the future of healthcare.
Cost of Revenue: Key Insights for Johnson & Johnson and Veracyte, Inc.
Comparing Cost of Revenue Efficiency: Amgen Inc. vs Gilead Sciences, Inc.
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Gilead Sciences, Inc.
Cost of Revenue: Key Insights for Gilead Sciences, Inc. and Telix Pharmaceuticals Limited
Analyzing Cost of Revenue: Gilead Sciences, Inc. and Ionis Pharmaceuticals, Inc.
Gilead Sciences, Inc. vs Amneal Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs HUTCHMED (China) Limited
Cost of Revenue Comparison: Gilead Sciences, Inc. vs Mesoblast Limited
Analyzing Cost of Revenue: Lantheus Holdings, Inc. and Veracyte, Inc.
Comparing Cost of Revenue Efficiency: Amneal Pharmaceuticals, Inc. vs Veracyte, Inc.
Cost of Revenue Trends: Veracyte, Inc. vs Celldex Therapeutics, Inc.
Cost Insights: Breaking Down Veracyte, Inc. and Viridian Therapeutics, Inc.'s Expenses